Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Venetoclax and Bomedemstat in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Terrence J Bradley, MD
- Target Recruit Count
- 18
- Registration Number
- NCT05597306
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-10-05
- Target Recruit Count
- 60
- Registration Number
- NCT05594784
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-11-19
- Target Recruit Count
- 92
- Registration Number
- NCT05566054
- Locations
- 🇨🇳
The First Affliated Hospital of Soochow University, Suzhou, Jiangsu, China
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 6
- Registration Number
- NCT05564650
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: AzacitidineProcedure: Mutation Carrier ScreeningOther: Best PracticeProcedure: Bone Marrow AspirationProcedure: BiopsyDrug: Decitabine and CedazuridineProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: EnasidenibDrug: GilteritinibDrug: Daunorubicin HydrochlorideProcedure: EchocardiographyDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: VenetoclaxProcedure: Multigated Acquisition Scan
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2000
- Registration Number
- NCT05564390
- Locations
- 🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States
🇺🇸Marshfield Medical Center - Weston, Weston, Wisconsin, United States
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT05554419
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT05554393
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 335
- Registration Number
- NCT05554406
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05546060
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05536349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.